523 related articles for article (PubMed ID: 18612157)
21. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
23. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
24. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
[TBL] [Abstract][Full Text] [Related]
25. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
[TBL] [Abstract][Full Text] [Related]
26. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
27. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study.
Rocereto TF; Brady WE; Shahin MS; Hoffman JS; Small L; Rotmensch J; Mannel RS
Gynecol Oncol; 2010 Mar; 116(3):332-4. PubMed ID: 19922989
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
Henriksen R; Funa K; Wilander E; Bäckström T; Ridderheim M; Oberg K
Cancer Res; 1993 Oct; 53(19):4550-4. PubMed ID: 8402626
[TBL] [Abstract][Full Text] [Related]
30. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
[TBL] [Abstract][Full Text] [Related]
31. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
Rao K; Goodin S; Levitt MJ; Dave N; Shih WJ; Lin Y; Capanna T; Doyle-Lindrud S; Juvidian P; DiPaola RS
Prostate; 2005 Feb; 62(2):115-22. PubMed ID: 15389797
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
[TBL] [Abstract][Full Text] [Related]
34. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Kavanagh JJ; Sill MW; Ramirez PT; Warshal D; Pearl ML; Morgan MA
Int J Gynecol Cancer; 2008; 18(3):460-4. PubMed ID: 17854432
[TBL] [Abstract][Full Text] [Related]
35. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
36. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
37. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
[TBL] [Abstract][Full Text] [Related]
38. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium.
Dabrow MB; Francesco MR; McBrearty FX; Caradonna S
Gynecol Oncol; 1998 Oct; 71(1):29-37. PubMed ID: 9784315
[TBL] [Abstract][Full Text] [Related]
39. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
40. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]